Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G D Lewis

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1988
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cellsR M Hudziak, G D Lewis, M R Shalaby, et al.
Cancer Treatment and Research|January 1, 1992
Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapyJ W Park, R Stagg, G D Lewis, et al.
The Journal of Experimental Medicine|August 1, 1987
Inhibition of cytokine production by cyclosporin A and transforming growth factor betaT Espevik, I S Figari, M R Shalaby, et al.
Cancer Research|March 15, 1996
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsivenessG D Lewis, J A Lofgren, A E McMurtrey, et al.
Journal of Leukocyte Biology|March 1, 1987
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alphaM R Shalaby, M A Palladino, S E Hirabayashi, et al.
Environmental Pollution (Barking, Essex : 1987)|August 8, 2013
Biogeochemistry and community ecology in a spring-fed urban river following a major earthquakeNaomi S Wells, Tim J Clough, Leo M Condron, et al.
Growth Factors (Chur, Switzerland)|June 18, 1999
Receptor binding and biological activity of mammalian expressed sensory and motor neuron-derived factor (SMDF)P L Osheroff, S P Tsai, N Y Chiang, et al.
Journal of Biological Response Modifiers|October 1, 1990
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancerB M Fendly, C Kotts, D Vetterlein, et al.
Journal of Clinical Immunology|May 11, 1991
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinicH M Shepard, G D Lewis, J C Sarup, et al.
Science (New York, N.Y.)|May 22, 1992
Identification of heregulin, a specific activator of p185erbB2W E Holmes, M X Sliwkowski, R W Akita, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1988
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cellsR M Hudziak, G D Lewis, M R Shalaby, et al.
Cancer Treatment and Research|January 1, 1992
Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapyJ W Park, R Stagg, G D Lewis, et al.
The Journal of Experimental Medicine|August 1, 1987
Inhibition of cytokine production by cyclosporin A and transforming growth factor betaT Espevik, I S Figari, M R Shalaby, et al.
Cancer Research|March 15, 1996
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsivenessG D Lewis, J A Lofgren, A E McMurtrey, et al.
Journal of Leukocyte Biology|March 1, 1987
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alphaM R Shalaby, M A Palladino, S E Hirabayashi, et al.
Environmental Pollution (Barking, Essex : 1987)|August 8, 2013
Biogeochemistry and community ecology in a spring-fed urban river following a major earthquakeNaomi S Wells, Tim J Clough, Leo M Condron, et al.
Growth Factors (Chur, Switzerland)|June 18, 1999
Receptor binding and biological activity of mammalian expressed sensory and motor neuron-derived factor (SMDF)P L Osheroff, S P Tsai, N Y Chiang, et al.
Journal of Biological Response Modifiers|October 1, 1990
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancerB M Fendly, C Kotts, D Vetterlein, et al.
Journal of Clinical Immunology|May 11, 1991
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinicH M Shepard, G D Lewis, J C Sarup, et al.
Science (New York, N.Y.)|May 22, 1992
Identification of heregulin, a specific activator of p185erbB2W E Holmes, M X Sliwkowski, R W Akita, et al.
Pageof 5